Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;36(2):217-229.
doi: 10.1007/s40259-022-00523-z. Epub 2022 Mar 18.

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe

Affiliations
Review

Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe

Teresa Barcina Lacosta et al. BioDrugs. 2022 Mar.

Abstract

Background: To encourage the rational prescribing of biologics, payers across Europe have experimented with the implementation of benefit-sharing programs. Benefit-sharing programs are incentive programs that promote the use of 'best-value' off-patent biologics and biosimilars by driving changes in prescribing practices. The aim of these programs is to generate savings that can be shared among stakeholders involved (e.g. health authorities/payers, health care professionals, hospital managers/administration) and are generally used to improve the quality of health care and to increase patients' access to innovative services and medicines. However, the scarcity of information concerning the design, implementation and outcomes of benefit-sharing programs limits the transfer of knowledge to institutions aiming to adopt these types of incentive schemes in the future.

Objective: The aim of our study was to map benefit-sharing experiences across Europe, to compare their design and implementation characteristics and to assess the impact of the different benefit-sharing strategies on the use of 'best-value' biologics.

Method: Our approach was based on a literature review and on semi-structured interviews with payers/insurers, regulators, health care professionals and industry representatives.

Results: Our analysis revealed variable design characteristics for benefit-sharing programs, depending on the organization of the health care system, the specific timeframe, the care setting and the policy environment. All these aspects can influence the robustness of benefit-sharing initiatives and their potential to stay in effect over time. We also noted a generalized lack of transparency regarding the distribution of savings and how they are reinvested. This lack of transparency has raised questions on how to optimally implement benefit-sharing in the future.

Conclusions: To realize the full potential of benefit-sharing programs, we identify the importance of (i) setting up and timely monitoring success indicators for these programs; (ii) including quality of care and access to care parameters as success indicators; (iii) establishing clear pathways for the transparent redistribution/reinvestment of savings and (iv) transparently communicating with patients about the outcomes of benefit-sharing programs.

PubMed Disclaimer

Conflict of interest statement

SS, IH and AGV founded the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira (together with AGV and IH), Celltrion, Mundipharma and Pfizer, and he has had speaking engagements for Amgen and Sandoz. AGV is involved in consulting, advisory work and speaking engagements for a number of companies, a.o. AbbVie, Accord, Amgen, Biogen, Effik Benelux, Fresenius Kabi, Medicines for Europe, Pfizer/Hospira, Mundipharma, Roche, Sandoz. TBL and ATS declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. European Medicines Agency (EMA). Biosimilars in the EU. Information guide for healthcare professionals. 2019.
    1. European Medicines Agency (EMA). Medicines for Human Use Under Evaluation. 2021. https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation. Accessed 12 July 2021.
    1. European Medicines Agency (EMA). CHMP: Agendas, minutes and highlights. 2021. https://www.ema.europa.eu/en/committees/chmp/chmp-agendas-minutes-highli.... Accessed 12 July 2021.
    1. European Medicines Agency (EMA). Search engine EMA. Centrally authorised biosimilar medicines 2021. https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname.... Accessed 12 July 2021.
    1. IQVIA. The Impact of Biosimilar Competition in Europe. 2020.

Substances

LinkOut - more resources